Advanced Therapy Medicinal Products Market Regional Analysis:
North American Market Insights
The North America advanced therapy medicinal products market, amongst the market in all the other regions, is projected to hold the largest industry share of 44% by 2035. The market growth in North America is attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products. In 2022, around 600,000 deaths are attributed to the cancer cases and nearly 2 million new cases of cancer were diagnosed in the United States. Furthermore, in 2019, Pfizer Inc. a leading U.S. based pharmaceutical company announced the investment of USD 500 million to expand the gene therapy manufacturing unit in Sanford, North Carolina.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.
The global advanced therapy medicinal products market size was valued at over USD 45.2 billion in 2025 and is expected to expand at a CAGR of over 14.5%, surpassing USD 175.06 billion revenue by 2035.
North America advanced therapy medicinal products market is predicted to capture 44% share by 2035, driven by higher cases of cancer and neurological disorders and private investment.
Key players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
